Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT05285072 Recruiting - Clinical trials for Vascular Graft Infection

Siderophores for Imaging Infection Using 68Ga-DFO

GaDFO
Start date: March 15, 2022
Phase:
Study type: Observational

This is a single center pilot study involving a single study visit for participants, with remote follow up data collected at 24 hours. Follow up at 3 months and 6 months later occurs as standard of care. The purpose of the study is to find out if a new type of imaging tracer (68Ga-DFO) can be used to show infection in patients with vascular grafts using PET/CT scans. These infections may be associated with significant ill health and mortality and can be difficult to diagnose. Effective treatments can require major surgery and long-term antibiotic therapy which may not be well tolerated nor feasible. Development of new imaging tracers that could detect bacteria causing graft infections with PET-CT scanners has great potential to benefit patients being considered for vascular surgery. A PET-CT scan combines images from a CT (Computerised Tomography) scan and a PET (Positron Emission Tomography) scan. The CT scan takes a series of X-rays across the organs inside the body. The PET scan uses a mildly radioactive tracer to show up areas of activity inside the body. The 68Ga-DFO tracer mimics particles that bacteria make to take up iron from the body to help them grow. The investigators hope this new tracer will go to areas where bacteria are causing infection and tell if the graft is infected. The investigators hope this type of tracer could be a better way to show infection than the tests currently used to diagnose infection.

NCT ID: NCT05284318 Recruiting - Clinical trials for Anti-Bacterial Agents

Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.

PACER-PJI
Start date: December 1, 2021
Phase:
Study type: Observational [Patient Registry]

This is a multicenter prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before phase II revision surgery. Eligible patients will be included in this study after signing the informed consent form. After the second stage revision, according to the patient's symptoms and examination results, the attending physician used a reasonable antibiotic treatment scheme (including intravenous and oral medication). All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the time points of 1, 3, 6, 12, 18 and 24 months after the start of antibiotic treatment after phase II revision. The infection control rate of patients was evaluated by follow-up at least 2 years after operation, so as to analyze the effect of antibiotic treatment course after two-stage revision of periprosthetic joint infection.

NCT ID: NCT05283239 Recruiting - HPV Infection Clinical Trials

Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection

Start date: January 1, 2022
Phase:
Study type: Observational

Clinically, patients with persistent HR-HPV infection for more than 18 months or HR-HPV infection with CIN2 + need regular colposcopic biopsy to assess the outcome and progression of the disease. A total of 1000 participants with persistent HR-HPV infection (100 cases/center) were recruited from multiple centers, and HPV integration status and vaginal flora diversity were sequenced at baseline, 6th month, 12th month and 24th month, respectively, through prospective cohort studies. And to evaluate the influence of HPV integration status and flora changes on the prognosis of women with persistent HR-HPV infection.

NCT ID: NCT05282485 Recruiting - HIV Clinical Trials

Mitigating Infectious Morbidity and Growth Deficits in HIV Exposed Uninfected infanTs With Human Milk Oligosaccharides

MIGH-T MO
Start date: June 2, 2022
Phase: N/A
Study type: Interventional

Primary Objective: - To evaluate the effects of synbiotics on infectious morbidity and growth while it is in place from 4 to 24 weeks of age. - To evaluate the effects of synbiotics on infectious morbidity and growth from 4 to 48 weeks of age. Secondary Objectives: - To evaluate the effects of synbiotics on growth from 4 to 72 weeks of age. - To evaluate the effects of synbiotics on infant neurodevelopment at 48 and 72 weeks of age. - To evaluate the effects of synbiotics on biological measurements while it is in place from 4 to 24 weeks of age. - To evaluate the effects of synbiotics on biological measurements from 4 to 48 weeks of age. - To evaluate the effects of synbiotics on gut microbiome and fecal short chain fatty acids from 4 to 72 weeks of age. - To investigate feasibility, acceptance, tolerability, and behavioral adherence with the intervention. - To investigate whether the synbiotics reduces infectious morbidity and improves growth in CHEU relative to CHUU. - To investigate whether infant gut microbiota composition, maturity and function, and markers of inflammation and HMOs at baseline and over time are associated with morbidity and poor growth in CHEU and CHUU.

NCT ID: NCT05275335 Recruiting - Burns Clinical Trials

Understanding the Burn Wound Microbiome: Comparing Traditional Wound Cultures to Next Generation Sequencing Technology

Start date: November 1, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this investigation is to better understand the wound microbiome in burn wounds and the role it plays in outcomes and complications related to treatment.

NCT ID: NCT05266898 Recruiting - Clinical trials for Human Immunodeficiency Virus

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

AGO-Gard
Start date: November 30, 2022
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objective of the study is to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series. The clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes.

NCT ID: NCT05266807 Recruiting - Clinical trials for Clostridioides Difficile Infection

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

FENDER
Start date: August 16, 2022
Phase: Phase 3
Study type: Interventional

The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin or fidaxomicin) in severe and non-severe first episode and first recurrence of Clostridioides difficile infection (CDI). Experimental arm: antibiotic treatment (vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days) followed by FMT by oral capsules (one FMT, i.e. 20 FMT capsules given on 2 consecutive days, and followed by a 2nd FMT in severe CDI). Control Arm: vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days.

NCT ID: NCT05264402 Recruiting - Clinical trials for Catheter-related Bloodstream Infection

Comparison of Early Phase Infections Risk Between Midline and Piccline Caheters: MIDLINE AND PICCLINE CATHETERS

PICCORMID
Start date: November 15, 2021
Phase:
Study type: Observational

A long-term venous access is frequently required in patient management. Currently, it is ensured by using the long peripheral intravenous catheters (Midline) or peripheral inserted central catheters (PICC line). Either is inserted into a peripheral vein of the upper arm and extends to the distal axillary vein. If the indications for the two catheters can sometimes be debated, the Midline catheter seems to be more and more used. The complications related to the use of PICC lines have been well described in literature, whereas the comparison of the two catheter-related complications has been less analysed. The aim of this study is to compare the incidences of catheter-related bloodstream infections linked to PICCs and Midlines.

NCT ID: NCT05259761 Recruiting - HIV Infections Clinical Trials

Overcoming Geography With Technology: Medical Drones Project

Start date: September 22, 2021
Phase:
Study type: Observational

In this study, the investigators shall evaluate the use unmanned air vehicles (medical drones) to deliver ART to adult patients eligible/enrolled in community DSD models in Bufumira Islands, Kalangala district. The geography of the islands is ideal for this project because of the flat landscape and water coverage. The investigators hypothesize that the use of drones would be acceptable to patients and stakeholders, reduce facility drug stock outs, increase retention in care by 10% in intervention (at 12 months) compared to the control health centres and be cost neutral (to the patients and health sector perspectives). The investigators will also undertake evaluation of an efficient sample delivery system using medical drones especially for expansive rural areas like Moyo and Adjumani.

NCT ID: NCT05254990 Recruiting - Severe COVID-19 Clinical Trials

Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Start date: April 6, 2022
Phase: Phase 3
Study type: Interventional

Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.